M M Reidenberg

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi A new look at the profession of clinical pharmacology
    M M Reidenberg
    Weill Cornell Medical College, New York, New York, USA
    Clin Pharmacol Ther 83:213-7. 2008
  2. ncbi Drug labeling should be kept current
    Anil Rajpal
    Department of Pharmacology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Pharmacol Ther 73:4-6. 2003
  3. ncbi Are drugs for rare diseases "essential"?
    Marcus M Reidenberg
    Bull World Health Organ 84:686. 2006
  4. ncbi Prosecution of physicians for prescribing opioids to patients
    M M Reidenberg
    Department of Pharmacology, Joan and Sanford I Weill Medical College of Cornell University, New York, New York, USA
    Clin Pharmacol Ther 81:903-6. 2007
  5. ncbi Early research on renal function and drug action
    Marcus M Reidenberg
    Weill Cornell Medical College, 1300 York Ave LC 423, New York, NY 10065, USA
    J Clin Pharmacol 52:7S-9S. 2012
  6. ncbi Improving how we evaluate the toxicity of approved drugs
    Marcus M Reidenberg
    Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Pharmacol Ther 80:1-6. 2006
  7. ncbi World Health Organization program for the selection and use of essential medicines
    M M Reidenberg
    Department of Pharmacology, Joan and Sanford I Weill Medical College of Cornell University, New York, New York, USA
    Clin Pharmacol Ther 81:603-6. 2007
  8. ncbi Benefit/risk ratio of statins in primary prevention
    M M Reidenberg
    Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA
    Clin Pharmacol Ther 83:498-500. 2008
  9. ncbi The pros and cons of essential medicines for rich countries
    Marcus M Reidenberg
    Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    BMJ 329:1172. 2004
  10. ncbi Evolving ways that drug therapy is individualized
    Marcus M Reidenberg
    Department of Pharmacology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Pharmacol Ther 74:197-202. 2003

Collaborators

Detail Information

Publications28

  1. ncbi A new look at the profession of clinical pharmacology
    M M Reidenberg
    Weill Cornell Medical College, New York, New York, USA
    Clin Pharmacol Ther 83:213-7. 2008
    ..People who do not identify themselves as clinical pharmacologists do much research on drug effects in humans. The professional clinical pharmacologist's role must be re-evaluated in the context of society's needs and sources of funding...
  2. ncbi Drug labeling should be kept current
    Anil Rajpal
    Department of Pharmacology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Pharmacol Ther 73:4-6. 2003
  3. ncbi Are drugs for rare diseases "essential"?
    Marcus M Reidenberg
    Bull World Health Organ 84:686. 2006
  4. ncbi Prosecution of physicians for prescribing opioids to patients
    M M Reidenberg
    Department of Pharmacology, Joan and Sanford I Weill Medical College of Cornell University, New York, New York, USA
    Clin Pharmacol Ther 81:903-6. 2007
    ....
  5. ncbi Early research on renal function and drug action
    Marcus M Reidenberg
    Weill Cornell Medical College, 1300 York Ave LC 423, New York, NY 10065, USA
    J Clin Pharmacol 52:7S-9S. 2012
    ..This knowledge makes the response of an azotemic patient to a specific dose of a specific drug more predictable than before. This predictability makes drug therapy both safer and more effective for azotemic patients...
  6. ncbi Improving how we evaluate the toxicity of approved drugs
    Marcus M Reidenberg
    Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Pharmacol Ther 80:1-6. 2006
  7. ncbi World Health Organization program for the selection and use of essential medicines
    M M Reidenberg
    Department of Pharmacology, Joan and Sanford I Weill Medical College of Cornell University, New York, New York, USA
    Clin Pharmacol Ther 81:603-6. 2007
    ..With all societies dealing with the rising cost of medical care and having to make choices, the concept of essential medicines is a relevant to all now as it was to countries with limited resources when the WHO program started in 1975...
  8. ncbi Benefit/risk ratio of statins in primary prevention
    M M Reidenberg
    Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA
    Clin Pharmacol Ther 83:498-500. 2008
  9. ncbi The pros and cons of essential medicines for rich countries
    Marcus M Reidenberg
    Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    BMJ 329:1172. 2004
  10. ncbi Evolving ways that drug therapy is individualized
    Marcus M Reidenberg
    Department of Pharmacology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Pharmacol Ther 74:197-202. 2003
  11. ncbi Essential medicines for the whole world
    M M Reidenberg
    Division of Clinical Pharmacology, Cornell University Medical College, New York, New York, USA
    Clin Pharmacol Ther 82:500-3. 2007
    ..Basically, the concept is that medicines needed to satisfy the priority health-care needs of a population should be made available at all times to everyone in the population within the context of a functioning health-care system...
  12. ncbi Can the selection and use of essential medicines decrease inappropriate drug use?
    M M Reidenberg
    Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA
    Clin Pharmacol Ther 85:581-3. 2009
    ..Implementing the essential medicines concept will decrease inappropriate drug use. A much more global, comprehensive, and committed approach needs to be taken by all of us to eliminate it...
  13. ncbi Conflict of interest and medical publication
    Marcus M Reidenberg
    Dept of Pharmacology, Weill Medical College of Cornell University, 1300 York Avenue, New York, New York 10021, USA
    Sci Eng Ethics 8:455-7. 2002
    ..This can be enforced by ethical committees if they refuse to approve studies of investigators and sponsors who have failed to publish earlier studies...
  14. ncbi Drug discontinuation effects are part of the pharmacology of a drug
    Marcus M Reidenberg
    Weill Cornell Medical College, 1300 York Ave, New York, NY 10065, USA
    J Pharmacol Exp Ther 339:324-8. 2011
    ..The possibility of discontinuation syndromes has usually been neglected until adverse clinical events force them to be noticed. Attention to the possibility of drug discontinuation effects is an important part of drug safety evaluation...
  15. ncbi Environmental inhibition of 11beta-hydroxysteroid dehydrogenase
    M M Reidenberg
    Department of Pharmacology Box 70 Room LC 428, Weill Medical College, 1300 York Avenue, New York, NY 10021, USA
    Toxicology 144:107-11. 2000
    ..The importance of dietary and other exogenous inhibitors of this enzyme in electrolyte metabolism remains to be determined...
  16. ncbi Cortisol metabolism in hypertensive patients who do and do not develop hypokalemia from diuretics
    D L Santini
    Department of Medicine, Cornnell University Medical College, New York, New York 10021, USA
    Am J Hypertens 8:516-9. 1995
    ..We failed to find a metabolic predisposition to the development of hypokalemia by diuretic treatment...
  17. ncbi The risk of disciplinary action by state medical boards against physicians prescribing opioids
    Jack Richard
    Department of Medicine, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10021, USA
    J Pain Symptom Manage 29:206-12. 2005
    ..The actual risk of an American physician being disciplined by a state medical board for treating a real patient with opioids for a painful medical condition is virtually nonexistent...
  18. ncbi The risk of action by the Drug Enforcement Administration against physicians prescribing opioids for pain
    Beth Jung
    Department of Pharmacology, Joan and Sandford I. Weill Medical College of Cornell University, New York, NY 10021, USA
    Pain Med 7:353-7. 2006
    ..CONCLUSION: When adequate documentation exists in the medical record, the risk of civil, criminal, or administrative action being taken by the DEA against a physician for prescribing opioids for a chronic pain patient is small...
  19. ncbi What has been the impact of the concept of essential drugs?
    Micha Levy
    Hadassah University Hospital, Jerusalem, Israel
    Clin Pharmacol Ther 73:275-8. 2003
  20. ncbi Physicians being deceived
    Beth Jung
    Department of Pharmacology, Joan and Sanford I Weill Medical College of Cornell University, New York, NY 10021, USA
    Pain Med 8:433-7. 2007
    ..This study was to determine how readily physicians can tell that patients lie...
  21. ncbi Informed consent or acknowledgment of disclosure
    Marcus M Reidenberg
    Clin Pharmacol Ther 78:439-40. 2005
  22. ncbi Sponsorship, authorship, and accountability
    Marcus M Reidenberg
    N Engl J Med 346:290-2. 2002
  23. ncbi Rational prescribing of essential medicines
    Marcus M Reidenberg
    Clin Pharmacol Ther 74:195. 2003
  24. ncbi Issues in developing the medical scientist, Part 3: Evaluation of scientific achievement (essay by and interview with Marcus M. Reidenberg, MD)
    Marcus M Reidenberg
    J Investig Med 52:361-3. 2004
  25. ncbi Statins for primary prevention of coronary artery disease
    Marcus M Reidenberg
    Lancet 369:1078; author reply 1079. 2007
  26. ncbi Statins, lack of energy and ubiquinone
    Marcus M Reidenberg
    Br J Clin Pharmacol 59:606-7. 2005
  27. ncbi Interpretation of opioid levels: comparison of levels during chronic pain therapy to levels from forensic autopsies
    Beth F Jung
    Department of Pharmacology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Pharmacol Ther 77:324-34. 2005
  28. ncbi Clinical trials report card
    Marcus M Reidenberg
    N Engl J Med 354:1426-9; author reply 1426-9. 2006